// App-Quantinova.ai

: PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment

Researchers

Presenter

  • Tengteng Yu

Principal Investigators

  • Mu Hao

  • Hailin Chen

  • Kenneth Wen

  • Tingjian Wang

  • Thomas C.M Smits

  • Mehmet K. Samur

  • Eugenio Morelli

  • Lijie Xing

  • Liang Lin

  • Jun Qi

  • Gang An

  • Nikhil C Munshi

  • Yu-Tzu Tai

  • Lugui Qiu

  • Kenneth C. Anderson

Medical Centers

  • Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

  • Department of Data Science, Dana-Farber Cancer Institute, Boston, MA

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

  • Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

  • Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • B-cell lymphoma-extra large

  • B-cell lymphoma 2

  • Natural Killer cells

  • Peripheral blood mononuclear cell

  • Cluster of Differentiation 107 Antigen-Like Family Member A

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Cluster of Differentiation 2AP

  • Cyclin D1

  • Cyclin D2

  • Cluster of Differentiation 38

  • Programmed death-ligand 1

  • Interferon-alpha

  • Interferon-gamma

  • Interleukin 10

  • Signal Transducer And Activator Of Transcription 1

  • PI3K/AKT

Drug/Treatment

  • daratumumab Intravenous

  • Isatuximab

  • Interferon

  • Interferon Gamma

  • IFN-lambda

  • Interleukin-10

Outcome

  • N/A


Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A